Investigational Regenerative Pharmacologic Therapy
Phase 1Small molecule
Investigational Regenerative Pharmacologic Therapy is one of 13 small molecule programs targeting Sensorineural Hearing Loss. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Sensorineural Hearing Loss
#DrugCompanyPhaseTrials
1Trexall
Alnylam PharmaceuticalsApproved
Aricept
EisaiApproved
Valcyte
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Rayos
RRoxane Laboratories
Approved
Decadron
AAspen Global Incorporated
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Local Anesthetic
RRennes University Hospital
Phase 3
Platelet Rich Plasma
ZZagazig University
Phase 3
Combination
GSKPhase 1
AM-111
AAuris Medical AG
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- TTruway Health, Inc.